Imaging and blood testing to back new ovarian cancer policy
This article was originally published in Clinica
Serological and radiological testing will be used in England and Wales to monitor the effectiveness of the drug, Caelyx (doxorubicin), in halting the progression of advanced ovarian cancer, if the final appraisal determination issued this week by the UK National Institute for Clinical Excellence (NICE) becomes guidance.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.